Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Minerva Ginecologica 2017 June;69(3) > Minerva Ginecologica 2017 June;69(3):269-85

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA GINECOLOGICA

Rivista di Ostetricia e Ginecologia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEW  


Minerva Ginecologica 2017 June;69(3):269-85

DOI: 10.23736/S0026-4784.17.04043-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Current evidence and emerging drug therapies for overactive bladder

Matthew IZETT, Martino ZACCHE, Ganesh THIAGAMOORTHY, Dudley ROBINSON, Linda CARDOZO

Department of Urogynecology, King’s College Hospital NHS Foundation Trust, London, UK


PDF  


Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilizing health resources. Antimuscarinic therapy has been the mainstay of treatment and is well supported within the literature and guidelines. However, compliance is poor due to lack of efficacy and adverse events leading to the development of novel therapies. Mirabegron, the B3-adrenoreceptor agonist has emerged as an evidence-based alternative first or second line therapy. Two decades after its first clinical application for overactive bladder, intravesical botulinum toxin is now an important part of any clinician’s armamentarium for refractory cases. Despite these therapeutic options many patients find therapies ineffective or have adverse events. This has resulted in ongoing developments in the understanding of overactive bladder, potential new drugs and combination therapies, which this paper intends to review.


KEY WORDS: Urinary bladder, overactive - Urinary incontinence - Drug therapy

inizio pagina

Publication History

Issue published online: April 5, 2017
Article first published online: March 16, 2017

Per citare questo articolo

Izett M, Zacche M, Thiagamoorthy G, Robinson D, Cardozo L. Current evidence and emerging drug therapies for overactive bladder. Minerva Ginecol 2017;69:269-85. DOI: 10.23736/S0026-4784.17.04043-6

Corresponding author e-mail

linda@lindacardozo.co.uk